Kura Oncology

KURA

Market cap $859M

Kura Oncology, Inc. (KURA) Discusses Updated Data on Darlifarnib and Cabozantinib Combination in Advanced Renal Cell Carcinoma Transcript

The FIT-001 study is evaluating darlifarnib (KO-2806) in patients with RCC at once-daily doses of 3 mg, 5 mg, or 8 mg alternating 7 days on and off in combination with cabozantinib at once-daily doses of 60 mg or 40 mg.

Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy

Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy

SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on April 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 153,750 shares of common stock to six (6) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Kura Oncology (KURA) is reiterated as a Strong Buy, leveraging Komzifti's differentiated safety profile and substantial cash position for asymmetric upside. KURA's 2026 revenue expectations are achievable, requiring only 16% market penetration in NPM1-m R/R AML, supported by rapid payer coverage and favorable launch dynamics. The partnership with Kyowa Kirin caps upside but de-risks execution, with KURA booking all US sales and benefiting from milestone payments and cost sharing.

Kura Oncology, Inc. (KURA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on March 2, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 44,700 shares of common stock to four (4) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Kura Oncology, Inc. (KURA) Q4 2025 Earnings Call Transcript

Kura Oncology (KURA) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.22 per share a year ago.